In a therapy-like paradigm, suppressing astrocyte ApoE4 toned down tau accumulation, reined in microglia, and assuaged neurodegeneration. Treated mice resumed building nests.
New research implicates IL-6 signaling and even Aβ42 itself as BACE targets, complicating scientists’ efforts to resurrect BACE inhibitors at a lower dose.
Data from Phase 3 trials of elenbecestat show no harm to cognition, leaving open a chance that the drugs could be used safely in the future.
The first whole-genome manipulation of protein expression in neurons by CRISPR uncovers a deadly chain of events. Poor processing by lysosomes leads to a build-up of lipids and iron that revs up oxidative stress, killing neurons via ferroptosis.
African Americans are more likely than non-Hispanic Caucasians to carry variants that curtail expression of TREM2, and are less likely to inherit a variant that enhances it. As a result, they have less soluble TREM2 in their cerebrospinal fluid.
By shifting to home nursing and telemedicine, clinical researchers kept inching ahead during lockdowns.
At AD/PD 2021, clinicians described neurological symptoms and tissue damage in the brains of older people who died from severe COVID-19.
In the negative Phase 2 trial of prasinezumab, populations with more rapid decline benefited; this informed the design of a new Phase 2b study.
Both shy and funny, Allsop was a pioneer of modern Alzheimer's research.
Two mouse models presented at AD/PD may hand scientists more translationally relevant tools to explore LOAD pathophysiology and treatment. The tricks: targeted replacement and knocking in multiple GWAS variants.
As life expectancy increases in countries such as Nigeria, Brazil, China, and others, so does the number of people with dementia. How to provide modern care for them?
Researchers envision p-tau-based blood tests for Alzheimer’s disease within a few years, but maybe not a stand-alone test.
The field is shifting from targeting tau’s tips to its mid-region, especially where tau binds microtubules. Several new candidates are in the clinic; whether the strategy will work remains to be seen.
New data presented at the AD/PD conference offer the first evidence that a brain-shuttle strategy can work in people; the lecanemab and aducanumab antibody programs offer small updates.
A new PET tracer. Plasma glial fibrillary acidic protein. Two new, promising surrogates for astrogliosis are filling in the Alzheimer’s biomarker toolbox. Both reflect Aβ amyloid better than they do tau tangles.